SPONSOR
Gustave Roussy, Cancer Campus, Grand Paris
Total Trials
8
Recruiting
8
Phases
Phase 1, Phase 2, Phase 2, Phase 4, Phase 3
Conditions studied: Breast Cancer MetastaticHER2-positive Metastatic Breast CancerHER2 Low Breast CarcinomaAdvanced Breast CancerSolid Tumor, AdultSolid Tumor, ChildhoodHematologic CancerHead and Neck CancerKidney CancerRenal Cell Cancer
NCT06298084 Phase 1, Phase 2
Recruiting
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
Breast Cancer Metastatic
NCT05481502
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult
NCT04842162 Phase 2
Recruiting
Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery
Head and Neck Cancer
NCT06934057 Phase 4
Recruiting
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Kidney Cancer
NCT03983369 Phase 3
Recruiting
Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults
Mucositis Oral
NCT07483983 Phase 2
Recruiting
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
Metastatic/Locally Advanced Non-Small-Cell Lung Cancer
NCT05283044
Recruiting
Implementing Precision Medicine in cOmmunity HospiTALs
Metastatic Cancer
NCT05215106 Phase 2
Recruiting
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Early Small (cT1N0) Triple Negative Breast Cancer